homovanillic acid has been researched along with Anankastic Personality in 16 studies
Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.
homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.
homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Concentrations of the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA), the dopamine metabolite homovanillic acid, and the noradrenaline metabolite 4-hydroxy-3-methoxyphenyl glycol were measured in CSF before and after three weeks' treatment of severe obsessive-compulsive disorder with clomipramine hydrochloride." | 9.05 | Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects. ( Asberg, M; Bertilsson, L; Mellström, B; Sjöqvist, F; Thorén, P; Träskman, L, 1980) |
| "The authors report on the successful treatment of obsessive-compulsive disorder (OCD) in three patients with the addition of risperidone to ongoing fluvoxamine treatment." | 7.73 | Successful treatment for obsessive-compulsive disorder with addition of low-dose risperidone to fluvoxamine: implications for plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor levels. ( Kaneko, S; Nakamura, J; Shinkai, K; Yoshimura, R, 2006) |
| "The CSF levels of corticotropin-releasing hormone, vasopressin, somatostatin, and oxytocin and of the monoamine metabolites 5-hydroxyindoleacetic acid, homovanillic acid, and 3-methoxy-4-hydroxyphenylglycol were measured in 17 children and adolescents with obsessive-compulsive disorder before and after long-term treatment with clomipramine." | 7.69 | Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine. ( Altemus, M; Leonard, HL; Potter, WZ; Rapoport, JL; Richter, D; Rubinow, DR; Swedo, SE, 1994) |
| "Concentrations of the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA), the dopamine metabolite homovanillic acid, and the noradrenaline metabolite 4-hydroxy-3-methoxyphenyl glycol were measured in CSF before and after three weeks' treatment of severe obsessive-compulsive disorder with clomipramine hydrochloride." | 5.05 | Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects. ( Asberg, M; Bertilsson, L; Mellström, B; Sjöqvist, F; Thorén, P; Träskman, L, 1980) |
| "The authors report on the successful treatment of obsessive-compulsive disorder (OCD) in three patients with the addition of risperidone to ongoing fluvoxamine treatment." | 3.73 | Successful treatment for obsessive-compulsive disorder with addition of low-dose risperidone to fluvoxamine: implications for plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor levels. ( Kaneko, S; Nakamura, J; Shinkai, K; Yoshimura, R, 2006) |
| "The CSF levels of corticotropin-releasing hormone, vasopressin, somatostatin, and oxytocin and of the monoamine metabolites 5-hydroxyindoleacetic acid, homovanillic acid, and 3-methoxy-4-hydroxyphenylglycol were measured in 17 children and adolescents with obsessive-compulsive disorder before and after long-term treatment with clomipramine." | 3.69 | Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine. ( Altemus, M; Leonard, HL; Potter, WZ; Rapoport, JL; Richter, D; Rubinow, DR; Swedo, SE, 1994) |
| "In light of prior data that the central administration of vasopressin in animals is associated with abnormal persistence of behaviors acquired under aversive conditioning, we studied the secretion of arginine vasopressin into the cerebrospinal fluid and plasma in patients with obsessive-compulsive disorder and controls." | 3.68 | Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder. ( Altemus, M; Demitrack, M; Dubbert, B; Gold, PW; Kalogeras, KT; Murphy, DL; Pigott, T, 1992) |
| "Depression was by far the most important factor." | 1.26 | Cortisol in the CSF of depressed and suicidal patients. ( Asberg, M; Bertilsson, L; Lantto, O; Schalling, D; Träskman, L; Tybring, G, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (37.50) | 18.7374 |
| 1990's | 6 (37.50) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Figee, M | 2 |
| de Koning, P | 1 |
| Klaassen, S | 1 |
| Vulink, N | 1 |
| Mantione, M | 1 |
| van den Munckhof, P | 2 |
| Schuurman, R | 1 |
| van Wingen, G | 1 |
| van Amelsvoort, T | 1 |
| Booij, J | 1 |
| Denys, D | 2 |
| de Koning, PP | 1 |
| Endert, E | 1 |
| Schuurman, PR | 1 |
| Storosum, JG | 1 |
| Fliers, E | 1 |
| Markianos, M | 1 |
| Lafazanos, S | 1 |
| Koutsis, G | 1 |
| Sfagos, C | 1 |
| Seretis, A | 1 |
| Yoshimura, R | 1 |
| Kaneko, S | 1 |
| Shinkai, K | 1 |
| Nakamura, J | 1 |
| Träskman, L | 2 |
| Tybring, G | 1 |
| Asberg, M | 2 |
| Bertilsson, L | 2 |
| Lantto, O | 1 |
| Schalling, D | 1 |
| Thorén, P | 1 |
| Mellström, B | 1 |
| Sjöqvist, F | 1 |
| Leckman, JF | 1 |
| Cohen, DJ | 1 |
| Altemus, M | 2 |
| Swedo, SE | 4 |
| Leonard, HL | 3 |
| Richter, D | 1 |
| Rubinow, DR | 1 |
| Potter, WZ | 4 |
| Rapoport, JL | 2 |
| Oades, RD | 1 |
| Röpcke, B | 1 |
| Eggers, C | 1 |
| Bridges, PK | 1 |
| Bartlett, JR | 1 |
| Sepping, P | 1 |
| Kantamaneni, BD | 1 |
| Curzon, G | 1 |
| Kruesi, MJ | 3 |
| Rettew, DC | 1 |
| Listwak, SJ | 1 |
| Berrettini, W | 1 |
| Stipetic, M | 2 |
| Hamburger, S | 1 |
| Gold, PW | 2 |
| Pigott, T | 1 |
| Kalogeras, KT | 1 |
| Demitrack, M | 1 |
| Dubbert, B | 1 |
| Murphy, DL | 2 |
| Hollander, E | 1 |
| Stein, DJ | 1 |
| Saoud, JB | 1 |
| DeCaria, CM | 1 |
| Cooper, TB | 1 |
| Trungold, S | 1 |
| Stanley, M | 1 |
| Liebowitz, MR | 1 |
| Benkelfat, C | 1 |
| Mefford, IN | 1 |
| Masters, CF | 1 |
| Nordahl, TE | 1 |
| King, AC | 1 |
| Cohen, RM | 1 |
| Hamburger, SD | 2 |
| Cheslow, DL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00004325] | 200 participants | Observational | 1988-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for homovanillic acid and Anankastic Personality
| Article | Year |
|---|---|
Recent advances in Gilles de la Tourette syndrome: implications for clinical practice and future research.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Compulsive | 1983 |
2 trials available for homovanillic acid and Anankastic Personality
| Article | Year |
|---|---|
Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects.
Topics: Adult; Clomipramine; Female; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Met | 1980 |
Effects of fenfluramine on plasma HVA in OCD.
Topics: Dopamine; Fenfluramine; Homovanillic Acid; Humans; Obsessive-Compulsive Disorder; Serotonin | 1992 |
13 other studies available for homovanillic acid and Anankastic Personality
| Article | Year |
|---|---|
Deep brain stimulation induces striatal dopamine release in obsessive-compulsive disorder.
Topics: Adult; Corpus Striatum; Deep Brain Stimulation; Dopamine; Female; Homovanillic Acid; Humans; Iodoben | 2014 |
Rapid effects of deep brain stimulation reactivation on symptoms and neuroendocrine parameters in obsessive-compulsive disorder.
Topics: Adult; Deep Brain Stimulation; Female; Glycopeptides; Growth Hormone; Homovanillic Acid; Humans; Mal | 2016 |
CSF neurotransmitter metabolites and neuropsychiatric symptomatology in patients with normal pressure hydrocephalus.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Chromatography, High Pressure Liquid; Dopamine; Femal | 2009 |
Successful treatment for obsessive-compulsive disorder with addition of low-dose risperidone to fluvoxamine: implications for plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor levels.
Topics: Adult; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Catecholamines; Dose-Response Relati | 2006 |
Cortisol in the CSF of depressed and suicidal patients.
Topics: Adjustment Disorders; Clomipramine; Depression; Female; Homovanillic Acid; Humans; Hydrocortisone; H | 1980 |
Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine.
Topics: Adolescent; Child; Clomipramine; Corticotropin-Releasing Hormone; Female; Homovanillic Acid; Humans; | 1994 |
Monoamine activity reflected in urine of young patients with obsessive compulsive disorder, psychosis with and without reality distortion and healthy subjects: an explorative analysis.
Topics: Adolescent; Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Creatinine; Dopamine; Epine | 1994 |
Precursors and metabolites of 5-hydroxytryptamine and dopamine in the ventricular cerebrospinal fluid of psychiatric patients.
Topics: Adult; Aged; Anxiety Disorders; Brain Diseases; Cerebral Ventricles; Depression; Female; Homovanilli | 1976 |
Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Arginine Vasopressin; Child; Clomipramine; Corticotr | 1992 |
Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Aged; Arginine Vasopressin; Corticotropin-Releasing Hormone; Female; Homovanillic | 1992 |
Plasma catecholamines and their metabolites in obsessive-compulsive disorder.
Topics: Adult; Catecholamines; Epinephrine; Female; Homovanillic Acid; Humans; Male; Methoxyhydroxyphenylgly | 1991 |
Concentration gradient of CSF monoamine metabolites in children and adolescents.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Child De | 1988 |
Lack of seasonal variation in pediatric lumbar cerebrospinal fluid neurotransmitter metabolite concentrations.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Female; | 1989 |